No Data
No Data
Shuanglu Pharmaceutical (002038.SZ): 2023 net profit pre-increased by 66%-100%
Gelonghui, January 26 | Shuanglu Pharmaceutical (002038.SZ) announced its 2023 annual results forecast. Net profit and profit attributable to shareholders of listed companies during the reporting period was about 39 million yuan to 47 million yuan, an increase of about 66%-100% over the same period of the previous year; net profit after deducting non-recurring profit and loss was about 20 million yuan to 250 million yuan, an increase of about 40%-75% over the same period last year; basic earnings per share were about 0.38 yuan/share - 0.46 yuan/share. During the reporting period, the company's net profit attributable to shareholders of listed companies increased significantly. The first is the company's non-recurring losses
Shuanglu Pharmaceutical (002038.SZ): Currently, sales of products such as oseltamivir, thymus pentapeptide, and interleukin-2 have increased markedly
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Does the company have oseltamivir and azithromycin-related products?” The company replied that at present, sales of the company's products such as oseltamivir, thymus pentapeptide, and interleukin-2 have increased markedly.
Shuanglu Pharmaceutical (002038.SZ): Gicabine is still in phase III clinical research
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Please tell me about the development progress of your gigacabine and febusil in China?” The company replied that gigabine is still in phase III clinical research, febusta has been conditionally listed in the US, and that the domestic listing application is under normal review.
Shuanglu Pharmaceutical (002038.SZ): Nippon Pharmaceutical has now completed phase III follow-up of all test subjects, and is expected to submit registration applications next year
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Is the company's GLP-1 formulation expected to be registered this year?” The company replied that the Japanese drug has now completed phase III clinical trials and is in the clinical data collation stage. Currently, it has completed follow-up of all phase III subjects, and it is expected that registration applications will be submitted next year.
Shuanglu Pharmaceutical (002038.SZ): The company has no Smegalotide R&D
Gelonghui November 20 | Shuanglu Pharmaceutical (002038.SZ) said on the investor interactive platform that the company has not developed simeglutide, but the company's GLP-1 long-acting drug, duracylotide, has now completed phase III clinical enrollment and is expected to complete clinical research in the first half of next year; the GLP-1 preparation, liraglutide, is in the clinical data compilation stage. It is expected that all phase III participants will be followed up. It is expected that registration applications will be submitted next year.
Shuanglu Pharmaceutical (002038.SZ): No separate weight loss clinical studies were conducted in the GLP-1 clinical trials
On November 20, Gelonghui, on the investor interactive platform, some investors asked Shuanglu Pharmaceutical (002038.SZ), “Has the GLP-1 project currently being developed approved for obesity and overweight indications? “Don't answer by using methods such as GLP1 for lowering sugar and weight loss, etc.” The company replied that in the clinical trials of the company's GLP-1 projects, no separate weight loss clinical studies were conducted, but weight changes were observed as secondary efficacy indicators, and no marketing application has been submitted so far.
No Data